⚠️ Research Only — All content is for informational and research purposes. Not medical advice. Read full disclaimer

Selank

Also known as: TP-7, Selanc, Semax's cousin

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a modified analog of the naturally occurring immunomodulatory peptide tuftsin, designed with enhanced stability and pronounced anxiolytic and nootropic properties.

Last updated: February 1, 2025Reviewed by: PeptideHub Research Team

Selank is a 751.87 Da research peptide. Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a modified analog of the naturally occurring immunomodulatory peptide tuftsin, designed with enhanced stability and pronounced anxiolytic and nootropic properties.

Also called: TP-7, Selanc, Semax's cousin

751.87

Molecular Weight

Daltons

1

Strong Evidence

benefits

5

Studies Cited

peer-reviewed

250-500

Typical Dose

mcg

Overview

Selank is a synthetic peptide consisting of seven amino acids, developed by combining the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a stabilizing Pro-Gly-Pro sequence. This modification dramatically improves its biological half-life compared to native tuftsin. Selank has been approved as a pharmaceutical drug in Russia for the treatment of generalized anxiety disorder (GAD) and as a nootropic agent. Its dual mechanism; combining anxiolytic effects comparable to benzodiazepines with cognitive enhancement and immunomodulation, makes it unique among peptide therapeutics. Research has demonstrated that Selank influences GABAergic, serotonergic, and dopaminergic neurotransmission, modulates brain-derived neurotrophic factor (BDNF) expression, and regulates the balance of T-helper cell cytokines. Unlike benzodiazepines, Selank does not produce sedation, motor impairment, amnesia, or dependence at standard doses.

Key Takeaways: Selank

  • Strongest evidence supports Selank for anxiolytic effects
  • Research doses typically range from 250 to 500 mcg via intranasal spray
  • 1 benefits with strong evidence, 4 moderate, 1 preliminary
  • Half-life: Several minutes (native tuftsin); enhanced to ~30 min with PGP modification
  • 5 cited research studies in this guide

Mechanism of Action

Selank's anxiolytic effects are mediated primarily through modulation of the GABAergic system, specifically by influencing GABA-A receptor sensitivity and GABA metabolism in the brain. It increases the expression of the enzyme that synthesizes GABA (glutamic acid decarboxylase) while modulating GABA transaminase activity. Simultaneously, Selank influences serotonergic neurotransmission by affecting tryptophan hydroxylase expression and serotonin metabolism, particularly in the dorsal raphe nucleus and hippocampus. Its nootropic effects are linked to upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus, which supports neuroplasticity, memory consolidation, and learning. Selank also modulates the enkephalin-degrading enzymes, potentially increasing endogenous opioid peptide levels which contribute to its anxiolytic profile. As a tuftsin analog, Selank retains immunomodulatory activity, influencing the Th1/Th2 cytokine balance and enhancing natural killer cell activity and phagocytosis. Gene expression studies show Selank affects over 60 genes involved in neurotransmission, inflammation, and immune regulation.

Research Benefits

Selank at a Glance

Primary mechanism:

Selank's anxiolytic effects are mediated primarily through modulation of the GABAergic system, specifically by influencing GABA-A receptor sensitivity and GABA metabolism in the brain.

Top researched benefits:
Anxiolytic EffectsCognitive EnhancementImmunomodulationBDNF UpregulationNo Dependence ProfileAntiviral Properties

Anxiolytic Effects

Strong Evidence

Clinical studies in Russia demonstrate anxiolytic effects comparable to benzodiazepines in patients with generalized anxiety disorder, without sedation, cognitive impairment, or dependence. Approved as an anxiolytic medication in Russia.

Cognitive Enhancement

Moderate Evidence

Research shows improved memory consolidation, attention, and learning through BDNF upregulation and modulation of serotonergic and dopaminergic pathways in the hippocampus. Nootropic effects observed in both animal and human studies.

Immunomodulation

Moderate Evidence

As a tuftsin analog, Selank modulates immune function by influencing Th1/Th2 cytokine balance, enhancing monocyte and NK cell activity, and regulating inflammatory responses without immunosuppression.

BDNF Upregulation

Moderate Evidence

Studies demonstrate significant increases in brain-derived neurotrophic factor expression in the hippocampus, supporting neuroplasticity and potentially offering neuroprotective benefits.

No Dependence Profile

Moderate Evidence

Unlike benzodiazepines, clinical and preclinical research indicates Selank does not produce tolerance, physical dependence, withdrawal symptoms, or cognitive impairment at therapeutic doses.

Antiviral Properties

Preliminary

Preliminary research suggests Selank may have antiviral activity through enhancement of interferon production and modulation of innate immune pathways.

Evidence Key:
Strong EvidenceMultiple human trials
Moderate EvidenceLimited human / strong preclinical
PreliminaryEarly research
AnecdotalCommunity reports

Research Dosing Protocols

Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.

Research ProtocolDose RangeRoute
Russian pharmaceutical dose (nasal)250500 mcgIntranasal spray
Subcutaneous research protocol250500 mcgSubcutaneous injection
Higher-dose research protocol5001000 mcgIntranasal or subcutaneous

Frequency

1-3 times daily

Timing

Morning and/or early afternoon preferred; may be used before stressful events

Cycle Length

14-30 day courses typical in Russian clinical practice

Research Notes

  • 1The approved Russian pharmaceutical form is a 0.15% intranasal spray.
  • 2Intranasal delivery provides rapid brain penetration bypassing the blood-brain barrier.
  • 3Clinical courses in Russian medicine are typically 14 days, with breaks between courses.
  • 4Effects may be cumulative, with optimal benefits appearing after several days of use.
  • 5Selank does not produce sedation or impair motor function at standard doses.

Reconstitution Guide

Standard Reconstitution

Vial Size

5 mg

Bacteriostatic Water

2 mL

Concentration

25 mcg

per 0.1 mL (10 units)

Step-by-Step Guide

1

Gather Materials

Selank vial, bacteriostatic water, alcohol swabs, insulin syringes.

2

Equilibrate Temperature

Remove the vial from storage and allow it to reach room temperature (5-10 minutes).

3

Sanitize

Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.

4

Draw Water

Draw 2 mL of bacteriostatic water into a syringe.

5

Add Water to Vial

Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.

6

Mix Gently

Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.

7

Store Properly

Refrigerate at Refrigerated (2-8°C / 36-46°F) after reconstitution. Up to 21 days refrigerated after reconstitution.

Storage Temperature

Refrigerated (2-8°C / 36-46°F) after reconstitution

Shelf Life

Up to 21 days refrigerated after reconstitution

Important Notes

  • For intranasal use, reconstitute with bacteriostatic sodium chloride 0.9% solution.
  • For subcutaneous use, standard bacteriostatic water is appropriate.
  • Selank is sensitive to degradation; use within the recommended shelf life.
  • Protect from light and excessive heat.
  • Nasal spray bottles should be primed before first use.

Safety & Side Effects

Reported Side Effects

  • !Generally well-tolerated in clinical studies with a favorable safety profile
  • !Mild nasal irritation with intranasal administration
  • !Mild fatigue reported in some individuals
  • !Slight sedation at higher doses (uncommon at standard doses)
  • !Allergic reactions (rare)
  • !No significant cognitive impairment, motor disruption, or withdrawal symptoms reported
  • !No hepatotoxicity observed in clinical studies

Potential Interactions

  • May potentiate the effects of other GABAergic compounds (benzodiazepines, barbiturates, alcohol).
  • Potential additive effects with other anxiolytic or nootropic compounds.
  • May influence cytokine balance — caution with immunomodulatory medications.
  • Theoretical interaction with SSRIs/SNRIs due to serotonergic modulation.
  • No significant adverse interactions reported in Russian clinical practice at approved doses.

Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.

Research Studies

The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.

Selank administration affects the expression of some genes involved in GABAergic neurotransmission

Zozulya AA, et al.2008Bulletin of Experimental Biology and Medicine
PMID: 19489963

Demonstrated that Selank modulates the expression of genes involved in GABA synthesis, transport, and receptor function, providing molecular evidence for its anxiolytic mechanism.

Anxiolytic-like effect of selank in elevated plus-maze test

Seredenin SB, et al.1998Bulletin of Experimental Biology and Medicine

Preclinical study showing significant anxiolytic effects of Selank in standard anxiety models, comparable to diazepam but without sedative or muscle-relaxant side effects.

Effects of selank on cognitive functions and BDNF expression

Seredenin SB, et al.2013Bulletin of Experimental Biology and Medicine
PMID: 24137589

Showed Selank increases BDNF expression in the hippocampus and improves cognitive performance in learning and memory tasks, supporting its nootropic classification.

Selank has an immunomodulatory effect in patients with anxiety-asthenic disorders

Zozulya AA, et al.2008Zhurnal Nevrologii i Psikhiatrii

Clinical study demonstrating dual anxiolytic and immunomodulatory effects of Selank in patients with anxiety disorders, normalizing both psychological symptoms and immune parameters.

Molecular mechanism of action of Selank and its neuroprotective properties

Kozlovskii II, et al.2012Eksperimental'naia i Klinicheskaia Farmakologiia

thorough review of Selank's molecular mechanisms, including effects on gene expression profiles involving neurotransmission, inflammation, and neuroprotection pathways.

Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.

Frequently Asked Questions

Selank is a synthetic seven-amino-acid peptide derived from the natural immunomodulatory peptide tuftsin. It was developed in Russia and is approved there as a pharmaceutical for anxiety and as a nootropic. It has anxiolytic effects comparable to benzodiazepines without sedation or dependence.

Selank provides anxiolytic effects through GABA system modulation similar to benzodiazepines, but without their characteristic side effects, no sedation, no cognitive impairment, no motor dysfunction, no tolerance development, and no physical dependence or withdrawal.

Selank is primarily administered intranasally (nasal spray), which allows rapid absorption and brain penetration. It can also be administered subcutaneously. The intranasal route is preferred in Russian clinical practice.

Yes. Selank is approved as a pharmaceutical drug in Russia for generalized anxiety disorder and as a nootropic. It is not FDA-approved in the United States or approved by the EMA in Europe.

Both are Russian-developed peptides, but they have different origins and primary mechanisms. Selank is derived from tuftsin and is primarily anxiolytic/immunomodulatory. Semax is derived from ACTH and is primarily nootropic/neuroprotective. They are sometimes combined in research protocols.

No. One of Selank's key advantages over traditional anxiolytics is that it does not cause sedation or drowsiness at standard doses. It reduces anxiety while maintaining or even improving cognitive function and alertness.

⚠️

Research & Educational Use Only

All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.

The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.